Key facts
- Applause Pharma’s last known valuation is $2.4M (Oct 2025).
- It has raised $460K; the latest was Seed Round ($460K) in Oct 2025.
- Notable investors include UntroD, AS-Accelerator, ASTRANS.
- Status: Privately Held (backing).
Investors
3- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Applause Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Applause Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Applause Pharma
Developer of pharmaceutical products designed for treating and preventing diseases related to oxidative stress using rare earth elements. The company leverages the biochemical properties of rare earths to eliminate reactive oxygen species, inhibit enzymes, and trigger ionic reactions, enabling the medical businesses to advance pre-disease prevention and address the needs of an aging population.
- Sector
- Healthcare
- HQ
- Chuo, Japan
- Founded
- 2021
- Employees
- 10
- Website
- applausepharma.com/
- Ownership
- Privately Held (backing)
Applause Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Applause Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Applause Pharma in its N-PORT filings yet. We sweep new filings monthly.